Breast Cancer

FDA clears marketing of disease management tests

Published in Women's Health Weekly, November 14th, 2002

ChromaVision Medical Systems, Inc., (CVSN), a provider of automated cell-imaging systems and manufacturer of the ACIS digital microscope system, announced that the U.S. Food and Drug Administration (FDA) cleared for marketing the use of its ACIS system to perform two tests used to help physicians determine an appropriate course of treatment for breast cancer patients.

The cleared ACIS applications detect, measure, and quantify the presence of estrogen receptors and progesterone receptors (commonly referred to as ER/PR) at the cellular level, allowing physicians a more precise and quantitative understanding of the specific traits of individual cancer tumors. In this...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry